Intellia Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Intellia Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Intellia Therapeutics Inc
Rating: 1.07802775
Author: Trendlyne DVM scores

Momentum Trap

about

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

13.07 0.47 (3.73%)

53.73% Fall from 52W High

8.1M

XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Low Financial Strength

11.1 / 100

Expensive Valuation

12.0 / 100

Technically Neutral

52.0 / 100

Momentum Trap These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 77%

18 analysts

Intellia Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Intellia Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

53.73% Fall from 52W High

SWOT Analysis

Intellia Therapeutics Inc Live Price Chart

Intellia Therapeutics Inc Live Price Chart